Additionally, with the elevated risk of BCR among the stratum-positive group, patients demonstrated an elevated expression of mesenchymal-state markers even when compared to clinical groups of worse prognosis, i.e., stratum-positive N0 vs. stratum-negative N1, stratum-positive localized PC vs. stratum-negative locally advanced PC, stratum-positive PSA < 10 ng/mL vs. stratum-negative PSA > 20 ng/mL, hence explaining the BCR-related failure in these groups (Figure 2, Table 2). This evidence concerns the gene KLK3 and pachyonychia congenita.